Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Orally Administered BMS-986485 in Healthy Adult Participants (Part A), and a Conditional Open-label Study to Evaluate the Relative Bioavailability of Alternate Formulations of BMS-986485 in Healthy Adult Participants (Part B)

NCT07887763 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07887763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Orally Administered BMS-986485 in Healthy Adult Participants (Part A), and a Conditional Open-label Study to Evaluate the Relative Bioavailability of Alternate Formulations of BMS-986485 in Healthy Adult Participants (Part B)
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 3, 2026
Completion date
June 8, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers

Arms

As registered; 2 arms.

  • Part A: SAD ExperimentalBMS-986485, BMS-986485 matching placebo
  • Part B: Conditional rBA ExperimentalBMS-986485

Primary endpoints

Registered primary outcome measures; 18 primary.

  • Number of participants with Treatment Emergent Adverse Events (TEAEs) Up to approximately Day 29
  • Number of participants with Serious Adverse Events (SAEs) Up to approximately Day 29
  • Number of participants with Vital Signs abnormalities Up to approximately Day 29
  • Number of participants with Physical Examination abnormalities Up to approximately Day 29
  • Number of Participants with 12-Lead Electrocardiogram (ECG) abnormalities Up to approximately Day 9

+13 more primary endpoints

Lead sponsor's other trials

Bristol-Myers Squibb, most recent start first.